Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

41. Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis Full Text available with Trip Pro

found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. Methods: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted,, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival (...) Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis | Research Square Browse Tools & Services Your Cart See the published version of this article at . This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting

2020 Research Square

42. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Full Text available with Trip Pro

Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lynch syndrome is associated with an increased risk of colorectal cancer and with a broader spectrum of cancers, especially endometrial cancer. In 2011, our group reported long-term cancer outcomes (mean follow-up 55·7 months [SD 31·4]) for participants with Lynch syndrome enrolled (...) outcomes were monitored for at least 10 years from recruitment with English, Finnish, and Welsh participants being monitored for up to 20 years. The primary endpoint was development of colorectal cancer. Analysis was by intention to treat and per protocol. The trial is registered with the ISRCTN registry, number ISRCTN59521990.Between January, 1999, and March, 2005, 937 eligible patients with Lynch syndrome, mean age 45 years, commenced treatment, of whom 861 agreed to be randomly assigned

2020 Lancet

43. Polymorphisms of Folate-Metabolizing Enzymes (MTHFR, MTR and MTRR) and Colorectal Cancer Risk: An Updated Systematic Review and Meta-analysis of Case-control Studies Full Text available with Trip Pro

Polymorphisms of Folate-Metabolizing Enzymes (MTHFR, MTR and MTRR) and Colorectal Cancer Risk: An Updated Systematic Review and Meta-analysis of Case-control Studies Inplasy Protocol 387 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols

44. Genome wide meta-analysis of cDNA datasets reveals new target gene signatures of colorectal cancer based on systems biology approach Full Text available with Trip Pro

with the promotion of cell cycle progression in human colorectal cancer cells. Arch Biochem Biophys. 2014;564:52–66. 28. Wang HL, Hart J, Fan L, Mustafi R, Bissonnette M. Upregulation of glycogen synthase kinase 3beta in human colorectal adenocarcinomas correlates with accumulation of CTNNB1. Clin colorectal Cancer. 2011;10(1):30–6. 29. Gerling M, Büller NV, Kirn LM, Joost S, Frings O, Englert B, et al. Stromal Hedgehog signalling is downregulated in colon cancer and its restoration restrains tumour growth. Nat (...) , and therapy. OncoTargets Ther. 2017;10:3249–59. 33. Ungerbäck J, Belenki D, Jawad ul-Hassan A, Fredrikson M, Fransén K, Elander N, et al. Genetic variation and alterations of genes involved in NFκB/TNFAIP3-and NLRP3-inflammasome signaling affect susceptibility and outcome of colorectal cancer. Genetic Variation Carcinog. 2012;33(11):2126–34. 34. Selga E, Noé V, Ciudad CJ. Transcriptional regulation of aldo-keto reductase 1C1 in HT29 human colon cancer cells resistant to methotrexate: Role in the cell

2020 Journal of Biological Research-Thessaloniki

45. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, rand Full Text available with Trip Pro

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, rand Upfront FOLFOXIRI Plus Bevacizumab and Reintroduction After Progression Versus mFOLFOX6 Plus Bevacizumab Followed by FOLFIRI Plus Bevacizumab in the Treatment of Patients With Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label (...) FOLFOXIRI Plus Bevacizumab and Reintroduction After Progression Versus mFOLFOX6 Plus Bevacizumab Followed by FOLFIRI Plus Bevacizumab in the Treatment of Patients With Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised, Controlled Trial , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Collaborators, Affiliations Expand Collaborators GONO Foundation Investigators

2020 EvidenceUpdates

46. Simultaneous Versus Delayed Resection for Initially Resectable Synchronous Colorectal Cancer Liver Metastases: A Prospective, Open-label, Randomized, Controlled Trial

of Digestive, Endocrine, Oncologic and Liver Transplant Surgery, University Hospital, François Rabelais University, Tours, France. 10 Department of Hepatobiliary, Oncologic and Transplant Surgery, AP-HP, Paul Brousse Hospital, Paris-Sud University, Villejuif, France. PMID: 32209911 DOI: Item in Clipboard Full-text links Cite Abstract Objective: To answer whether synchronous colorectal cancer liver metastases (SLM) should be resected simultaneously with primary cancer or should be delayed. Summary (...) Simultaneous Versus Delayed Resection for Initially Resectable Synchronous Colorectal Cancer Liver Metastases: A Prospective, Open-label, Randomized, Controlled Trial Simultaneous Versus Delayed Resection for Initially Resectable Synchronous Colorectal Cancer Liver Metastases: A Prospective, Open-label, Randomized, Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several

2020 EvidenceUpdates

47. Long-Term Colorectal Cancer Incidence and Mortality After a Single Negative Screening Colonoscopy. (Abstract)

Long-Term Colorectal Cancer Incidence and Mortality After a Single Negative Screening Colonoscopy. Current guidelines recommend a 10-year interval between screening colonoscopies, but evidence is limited.To assess the long-term risk for colorectal cancer (CRC) and death from CRC after a high- and low-quality single negative screening colonoscopy.Observational study.Polish Colonoscopy Screening Program.Average-risk individuals aged 50 to 66 years who had a single negative colonoscopy (...) (no neoplastic findings).Standardized incidence ratios (SIRs) and standardized mortality ratios (SMRs) of CRC after high- and low-quality single negative screening colonoscopy. High-quality colonoscopy included a complete examination, with adequate bowel preparation, performed by endoscopists with an adenoma detection rate of 20% or greater.Among 165 887 individuals followed for up to 17.4 years, CRC incidence (0.28 [95% CI, 0.25 to 0.30]) and mortality (0.19 [CI, 0.16 to 0.21]) were 72% and 81% lower

2020 Annals of Internal Medicine

48. Clinical efficacy of adjuvant chemotherapy in the treatment of pT4 Stage II Colon Cancer with defective Mismatch Repair status. A protocol for systematic review and meta-analysis Full Text available with Trip Pro

Clinical efficacy of adjuvant chemotherapy in the treatment of pT4 Stage II Colon Cancer with defective Mismatch Repair status. A protocol for systematic review and meta-analysis Inplasy Protocol 252 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 International Platform of Registered Systematic Review and Meta-analysis Protocols

49. Physical activity interventions for disease-related physical and mental health during and following treatment in people with non-advanced colorectal cancer. (Abstract)

Physical activity interventions for disease-related physical and mental health during and following treatment in people with non-advanced colorectal cancer. Colorectal cancer is the third most commonly diagnosed cancer worldwide. A diagnosis of colorectal cancer and subsequent treatment can adversely affect an individuals physical and mental health. Benefits of physical activity interventions in alleviating treatment side effects have been demonstrated in other cancer populations. Given (...) that regular physical activity can decrease the risk of colorectal cancer, and cardiovascular fitness is a strong predictor of all-cause and cancer mortality risk, physical activity interventions may have a role to play in the colorectal cancer control continuum. Evidence of the efficacy of physical activity interventions in this population remains unclear.To assess the effectiveness and safety of physical activity interventions on the disease-related physical and mental health of individuals diagnosed

2020 Cochrane

50. Effect of Multimodal Prehabilitation vs Postoperative Rehabilitation on 30-Day Postoperative Complications for Frail Patients Undergoing Resection of Colorectal Cancer: A Randomized Clinical Trial Full Text available with Trip Pro

Effect of Multimodal Prehabilitation vs Postoperative Rehabilitation on 30-Day Postoperative Complications for Frail Patients Undergoing Resection of Colorectal Cancer: A Randomized Clinical Trial Effect of Multimodal Prehabilitation vs Postoperative Rehabilitation on 30-Day Postoperative Complications for Frail Patients Undergoing Resection of Colorectal Cancer: A Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete (...) results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation JAMA Surg Actions . 2020 Jan 22;155(3):233-242. doi: 10.1001/jamasurg.2019.5474. Online ahead of print. Effect of Multimodal Prehabilitation vs Postoperative Rehabilitation on 30-Day Postoperative Complications for Frail Patients Undergoing Resection of Colorectal Cancer: A Randomized Clinical Trial

2020 EvidenceUpdates

51. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial

TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial TAS-102 With or Without Bevacizumab in Patients With Chemorefractory Metastatic Colorectal Cancer: An Investigator-Initiated, Open-Label, Randomised, Phase 2 Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other (...) for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Lancet Oncol Actions . 2020 Mar;21(3):412-420. doi: 10.1016/S1470-2045(19)30827-7. Epub 2020 Jan 27. TAS-102 With or Without Bevacizumab in Patients With Chemorefractory Metastatic Colorectal Cancer: An Investigator-Initiated, Open-Label, Randomised, Phase 2 Trial , , , , , , , , , Affiliations Expand Affiliations 1 Department of Oncology, Odense University Hospital, Odense, Denmark; Department

2020 EvidenceUpdates

52. Stent expansion limited surgery versus emergency surgery for colon cancer with malignant bowel: A meta-analysis Full Text available with Trip Pro

Stent expansion limited surgery versus emergency surgery for colon cancer with malignant bowel: A meta-analysis INPLASY Protocol 193 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review Protocols

53. Coadjuvant Anti-VEGF A Therapy Improves Survival in Patients with Colorectal Cancer with Liver Metastasis: A Systematic Review Full Text available with Trip Pro

with Liver Metastasis: A Systematic Review. Gastrointestinal Disorders . 2020; 2(2):71-85. https://doi.org/10.3390/gidisord2020007 Chicago/Turabian Style Novo, Isabel; Campos, Bárbara; Pinto-Ribeiro, Filipa; Martins, Sandra F. 2020. "Coadjuvant Anti-VEGF A Therapy Improves Survival in Patients with Colorectal Cancer with Liver Metastasis: A Systematic Review" Gastrointest. Disord. 2, no. 2: 71-85. https://doi.org/10.3390/gidisord2020007 Find Other Styles Article Metrics No No Article Access Statistics (...) Coadjuvant Anti-VEGF A Therapy Improves Survival in Patients with Colorectal Cancer with Liver Metastasis: A Systematic Review GastrointestDisord | Free Full-Text | Coadjuvant Anti-VEGF A Therapy Improves Survival in Patients with Colorectal Cancer with Liver Metastasis: A Systematic Review Next Article in Journal Previous Article in Journal Information Initiatives Notice You can make submissions to other journals . You seem to have javascript disabled. Please note that many of the page

2020 Gastrointestinal Disorders

54. Prognostic Value of Lymph Node Yield on Long-term Survival in Colorectal Cancer Patients: A Systematic Review and Meta-analysis Full Text available with Trip Pro

Prognostic Value of Lymph Node Yield on Long-term Survival in Colorectal Cancer Patients: A Systematic Review and Meta-analysis Inplasy Protocol 88 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review Protocols

55. Regional Therapies for Colorectal Cancer Liver Metastases

Regional Therapies for Colorectal Cancer Liver Metastases Guideline 2-30a A Quality Initiative of the Program in Evidence-Based Care (PEBC), Ontario Health (Cancer Care Ontario) Regional Therapies for Colorectal Cancer Liver Metastases P. Karanicolas, R. Beecroft, R. Cosby, E. David, M. Kalyvas, E. Kennedy, G. Sapisochin, R. Wong, K. Zbuk and the Gastrointestinal Disease Site Group Report Date: March 10, 2020 For information about this document, please contact Dr. Paul Karanicolas or Dr. Robert (...) , Zbuk K. Regional therapies for colorectal cancer liver metastases. Toronto (ON): Ontario Health (Cancer Care Ontario); 2020March10. Program in Evidence-Based Care Guideline No.: 2-30a. Copyright This report is copyrighted by Ontario Health (Cancer Care Ontario); the report and the illustrations herein may not be reproduced without the express written permission of Ontario Health (Cancer Care Ontario). Ontario Health (Cancer Care Ontario) reserves the right at any time, and at its sole discretion

2020 Cancer Care Ontario

56. Treatment of Patients with Late-Stage Colorectal Cancer Resource-Stratified Guideline Full Text available with Trip Pro

emergency colon or rectal cancer surgery. If resection is not possible, then patients should receive palliative care. , Palliative colostomy should be considered in situations of malignant bowel obstruction. In the assessment of general symptoms, clinicians should determine a patient’s performance status and comorbid conditions, as they can influence the ability to receive and predict the benefit from medical treatment. Diagnosis Recommendations on the methods of diagnosis for patients with colorectal (...) , including frequency, depend on resource-based setting. Additional information is available at . INTRODUCTION Section: The purpose of this guideline is to provide expert guidance on the treatment and follow-up of patients with late-stage colorectal cancer to clinicians, public health leaders, and policymakers in all resource settings. The target population is people with late-stage colorectal cancer (metastatic TNM stage: T any, N any, M1; or unresectable TNM stage: T any, N any, M0 colon cancer

2020 American Society of Clinical Oncology Guidelines

57. Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer

between SSP and HPlocally,bowel preparation, or completeexcision, whereas a 5-year interval is favored if low concerns for consistency in distinction between SSP and HP locally, adequate bowel preparation, and confident complete excision. d See US Multi-Society Task Force recommendations for endoscopic removal of colorectal lesions. 69 e Assumes high confidence of complete resection. f Patients with cumulative >20 hyperplastic polyps distributed throughout the colon, with at least 5 being proximal (...) Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer US MULTI-SOCIETY TASK FORCE Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer Samir Gupta, 1,2,3 David Lieberman, 4 Joseph C. Anderson, 5,6,7 Carol A. Burke, 8 Jason A. Dominitz, 9,10 Tonya Kaltenbach, 11,12 Douglas J. Robertson, 5,6 Aasma Shaukat, 13,14 Sapna Syngal

2020 American Society for Gastrointestinal Endoscopy

58. Endoscopic Removal of Colorectal Lesions—Recommendations by the US Multi-Society Task Force on Colorectal Cancer

in Gastrointestinal Endoscopy, Gastroenterology, and The American Journal of Gastroenterology. Colonoscopy with polypectomy reduces the incidence of and mortality from colorectal cancer (CRC). 1,2 It is the cornerstone of effective prevention. 3 The National Polyp Study showed that removal of adenomas during colonoscopy is associated with a reduction in CRC mortality by up to 50% relative to population controls. 1,2 The lifetime risk to develop CRC in the United States is approximately 4.3%, with 90% of cases (...) GASTROINTESTINAL ENDOSCOPY Volume 91, No. 3 : 2020 www.giejournal.org Endoscopic removal of colorectal lesions Kaltenbach et alhistologic evaluation of resection tissue, as it removes all layers of the colon wall. 116,117 Suggested indications for endoscopic full-thickness resection include lesions 20 mm vs 81.2% for lesions 20 mm (PZ .0038). This may partly re?ect dif?culty assessing whether the lesion margin is fully contained in the cap when the lesion is fully drawn into the cap. Further outcomes studies

2020 American Society for Gastrointestinal Endoscopy

59. Does postoperative inflammation or sepsis generate neutrophil extracellular traps that influence colorectal cancer progression? A systematic review Full Text available with Trip Pro

Does postoperative inflammation or sepsis generate neutrophil extracellular traps that influence colorectal cancer progression? A systematic review Redirecting

2020 Surgery Open Science

60. Enhanced Recovery After Surgery in Emergency Resection for Obstructive Colorectal Cancer: A Systematic Review and Meta-analysis Full Text available with Trip Pro

for obstructive colorectal cancer - including a shorter length of hospitalization, a lower incidence of complication and quicker gastrointestinal recovery. Keywords enhanced recovery after surgery, colon cancer, rectum cancer, obstruction, emergency, systematic review, patient outcome Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Background Materials And Methods Results Discussion Conclusions Declarations References Tables Comments (0) Comments can take the form of short reviews, notes or questions (...) resection for obstructive colorectal cancer - including a shorter length of hospitalization, a lower incidence of complication and quicker gastrointestinal recovery. Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Background Materials And Methods Results Discussion Conclusions Declarations References Tables Comments (0) Comments can take the form of short reviews, notes or questions to the author. Comments will be posted immediately. If reported by the community, we will temporarily hide

2020 Research Square